Research and Markets (http://www.researchandmarkets.com/research/460547/pipeline_insight) has announced the addition of the "Pipeline Insight: Biologic Targeted Cancer Therapies - Next Generation Jostles for Market Position" report to their offering.
“Pipeline Insight: Biologic Targeted Cancer Therapies - Next Generation Jostles for Market Position”
Biologic molecular targeted therapies have driven much of the recent high growth in the oncology market and account for the three leading anticancer brands. As a consequence, a number of drug developers have tried to capitalize on the success of this therapy class, incorporating biologic agents into their pipelines.
Scope
- Examination of the biologic molecular targeted therapies pipeline with in-depth clinical and commercial profiles of Phase III candidates
- Seven major pharmaceutical market sales forecasts for Phase III pipeline products through to 2018 with product-specific assumptions
- Segmentation and analysis of the current biologic molecular targeted therapies pipeline by developmental phase, drug target and company
- Insight and analysis of market potential including commercial opportunity and discussion of unmet needs
Highlights of this title
There are currently 155 biologic molecular targeted therapies in development for cancer. Immunomodulatory/immunoconjugated agents and single target signal transduction inhibitors form the majority of the pipeline, accounting for 54% and 30% of the pipeline, respectively, while angiogenesis inhibitors/vascular disrupting agents account for 13%.